FibroGen Inc reports results for the quarter ended in June - Earnings Summary

Kyntra Bio

06/08/2024 23:21

* FibroGen Inc  FGEN.OQ  reported a quarterly adjusted loss
of 16
cents​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -90
cents.  The mean expectation of three analysts for the quarter
was for a loss of 32 cents per share. Wall Street expected
results to range from -45 cents to -24 cents per share.
    * Revenue rose 14.3% to $50.64 million from a year ago;
analysts
expected $34.66 million. 
    * FibroGen Inc's reported EPS for the quarter was a loss
of 16
cents​.
    * The company reported a quarterly loss of $15.54 million.
    * FibroGen Inc shares had fallen by 49.0% this quarter and
lost 48.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "sell"

Wall Street's median 12-month price target for FibroGen Inc is
$1.05 
This summary was machine generated from LSEG data August 6 at
10:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.32          -0.16          Beat
 Mar. 31 2024      -0.42          -0.33          Beat
 Dec. 31 2023      -0.42          -0.57          Missed
 Sep. 30 2023      -0.68          -0.52          Beat